Veracyte, Inc.
May 10, 2017

Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017

- New data reinforce role of Percepta® Bronchial Genomic Classifier and Envisia™ Genomic Classifier in diagnosis of difficult-to-distinguish pulmonary diseases -

SOUTH SAN FRANCISCO, Calif., May 10, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that data from multiple studies supporting use of the company's genomic classifiers to improve the diagnosis of lung cancer and idiopathic pulmonary fibrosis (IPF) will be presented at the American Thoracic Society 2017 International Conference (ATS 2017) being held May 19-24 in Washington, DC.

Two abstracts accepted for poster presentation at the conference will highlight data from studies supporting the clinical utility of the Percepta Bronchial Genomic Classifier. The Percepta classifier is used to improve the safety and accuracy of lung cancer screening and diagnosis by resolving inconclusive bronchoscopy results in patients undergoing evaluation for suspicious lung nodules or lesions.

Four additional abstracts will feature data demonstrating the clinical performance and utility of the Envisia Genomic Classifier, as well as the clinical need for the genomic test to resolve the significant challenges associated with IPF diagnosis. Veracyte launched the Envisia classifier, which is designed to improve the diagnosis of IPF without the need for risky, costly invasive procedures, during late 2016.

"Our Percepta and Envisia tests address real clinical needs by reducing the number of patients who must undergo risky, costly invasive procedures to resolve diagnostic uncertainty in lung cancer and IPF, respectively," said Bonnie Anderson, Veracyte's chief executive officer and chairman of the board. "The data that will be presented at ATS reflect our strong commitment to building the clinical evidence necessary to drive adoption and reimbursement of these novel genomic classifiers, so that more patients and medical professionals can benefit from them."

The following Percepta abstracts will be presented during ATS 2017:

Title:         

Alterations in Bronchial Airway MicroRNA Expression as a Diagnostic Biomarker for Lung Cancer (Abstract #1248; Poster #901)

Presenter:  

Ana Pavel, Boston University

Date/Time:  

Sunday, May 21, 9:15-9:45 a.m. ET

Location:      

Marquis Ballroom 3-4 (Level M2), Marriott Marquis Washington



Title:      

A Bronchial Airway Gene Expression Signature Associated with Adenocarcinoma vs. Squamous Cell Lung Cancer (Abstract #2372; Poster #738)

Presenter:     

J. Zhang, Boston University

Date/Time:   

Sunday, May 21, 11:15 a.m.-1:00 p.m. ET

Location:     

Area G, Hall B-C (Middle Building, Lower Level), Walter E. Washington Convention Center

The Envisia-related abstracts that will be presented at ATS 2017 comprise:

Title:        

Cohort Comparison Between Transbronchial Cryobiopsy and Surgical Lung Biopsy (SLB) in Patients Undergoing a Workup for Interstitial Lung Disease (ILD) from a Multicenter, Prospective Trial (Abstract #3464; Poster #965)

Presenter:     

M.P. Steele, M.D., Veteran's Administration Hospital

Date/Time:     

Monday, May 22, 11:15 a.m.-1:00 p.m. ET

Location:         

Area J, Hall B-C (Middle Building, Lower Level), Walter E. Washington Convention Center



Title:         

A Concordant Usual Interstitial (UIP) Diagnosis from Surgical Lung Biopsies (SLBs) Remains a Challenge for Patients with Interstitial Lung Disease (ILD) (Abstract #3463; Poster #964)

Presenter:  

T. Colby, M.D., Mayo Clinic

Date/Time:  

Monday, May 22, 11:15 a.m.-1:00 p.m. ET

Location:      

Area J, Hall B-C (Middle Building, Lower Level), Walter E. Washington Convention Center



Title:      

Prospective Validation of a Molecular Test for Usual Interstitial Pneumonia in Transbronchial Biopsies (Abstract #6792; Poster #616)

Presenter:     

Kevin K. Brown, National Jewish Health

Date/Time:   

Tuesday, May 23, 2:15-3:00 p.m. ET

Location:     

Room 206 (South Building, Level 2), Walter E. Washington Convention Center



Title:      

Analytical Performance of Envisia: a Genomic Classifier for Usual Interstitial Pneumonia Pattern (Abstract #6784; Poster #608)

Presenter:      

P. Sean Walsh, M.P.H., Veracyte

Date/Time:    

Tuesday, May 23, 2:15-3:00 p.m. ET

Location:      

Room 206 (South Building, Level 2), Walter E. Washington Convention Center

About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our ability to successfully scale the company and our belief that we are well positioned for profitable growth. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; the size of the market opportunity for our products; our ability to successfully achieve adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veracyte-announces-six-studies-highlighting-value-of-companys-genomic-classifiers-in-lung-cancer-and-idiopathic-pulmonary-fibrosis-to-be-presented-at-ats-2017-300454936.html

SOURCE Veracyte

News Provided by Acquire Media